Nigeria - 2016 - Health

NAFDAC Good Pharmacovigilance Practice Guidelines 2016

Ministry of Health, National Agency for Food and Drug Administration and Control, Nigeria

These guidelines apply to all entities that have the authorization to put medicinal products into the Nigerian market. These guidelines are intended to help all stakeholders comply with the provisions of the GVP regulations. They provide detailed guidance for marketing authorization holders on establishing and maintaining a pharmacovigilance system including its quality management, pharmacovigilance system master file, adverse reaction reporting, risk management, post-authorization safety studies, risk communication and pharmacovigilance audit.

Process Flow

Department of Pharmacovigilance and Post Marketing Surveillance

Office of the Director General NAFDAC

Office of the Permanent Secretary, Ministry of Health

Office of the Minister of State for Health

Office of the Minister of Health

Federal Executive Council

Compare Versions Please select two versions

NAFDAC Good Pharmacovigilance Practice Guidelines 2016 Current Version

January 2022

These guidelines apply to all entities that have the authorization to put medicinal products into the Nigerian market. These guidelines are intended to help all stakeholders comply with the provisions of the GVP regulations. They provide detailed guidance for marketing authorization holders on establishing and maintaining a pharmacovigilance system including its quality management, pharmacovigilance system master file, adverse reaction reporting, risk management, post-authorization safety studies, risk communication and pharmacovigilance audit.

Request Expert Analysis

Ask one of our policy analysts to take an in-depth look at this policy and provide you with a written summary. An additional cost may apply. Please let us know what questions you are looking to answer.

Thank you for requesting an expert analysis

A member of our team will review your request and reply back to the email address on file.